Anonymous ID: ccfaf6 Jan. 3, 2024, 1:27 p.m. No.20177250   🗄️.is 🔗kun   >>7260 >>7270 >>7351 >>7522 >>7565 >>7632

https://www.militarytimes.com/news/pentagon-congress/2023/12/21/dod-to-study-whether-covid-19-vaccine-helped-or-hurt-troops/

 

DOD to study whether COVID-19 vaccine helped or hurt troops

 

Lawmakers want military researchers to determine whether the COVID-19 vaccine caused more harm than good for service members.

 

Included in the annual defense authorization bill passed by Congress earlier this month is language calling for “a study to assess and evaluate any health conditions and adverse events arising in service members on active duty one year after receiving the first dose of a COVID-19 vaccine.” Researchers will be required to report their findings back to lawmakers in December 2024.

 

The vaccine has been a target of conservative lawmakers for years. In the fiscal 2023 defense authorization bill, lawmakers repealed the Defense Department’s mandate for all troops to receive the vaccine. This year’s bill also contains a host of provisions related to potential reenlistment of individuals kicked out of the ranks for refusing the shots.

 

But the research mandate — inserted by Republican House members during debate on the legislation — takes that further, again calling into question the safety of the vaccine.

 

The Centers for Disease Control and Prevention have said that “serious problems [linked to the vaccine] are rare and long-term side effects unlikely.” They have also said that medical research thus far has not shown any increased risk of death associated with receiving the inoculation, while contracting coronavirus does carry an increased risk of death.

 

But the agency has documented allergic reactions and heart problems in a small percentage of vaccine recipients.

 

The study will look at “any health condition developed after receiving such first dose, regardless of whether the condition is attributable to the receipt of such first dose,” and “an accounting of adverse events including hyperimmune response” linked to the vaccine.

 

House Republicans had also pushed for language prohibiting military leaders from mandating masks to prevent the spread of future COVID-19 outbreaks, but that language was dropped in final deliberations over the bill.

 

President Joe Biden is expected to sign the authorization bill into law before the end of the month.

 

About Leo Shane III

Leo covers Congress, Veterans Affairs and the White House for Military Times. He has covered Washington, D.C. since 2004, focusing on military personnel and veterans policies. His work has earned numerous honors, including a 2009 Polk award, a 2010 National Headliner Award, the IAVA Leadership in Journalism award and the VFW News Media award.

Anonymous ID: ccfaf6 Jan. 3, 2024, 1:28 p.m. No.20177255   🗄️.is 🔗kun   >>7283 >>7565 >>7632

https://twitter.com/DrJBhattacharya/status/1737116272608104499

 

Jay Bhattacharya

@DrJBhattacharya

In the Missouri v. Biden free speech case, the Biden Administration told the US Supreme Court that is needs to be able to force the social media companies to censor even true scientific information, or else people would die.

8:22 AM · Dec 19, 2023

·

Anonymous ID: ccfaf6 Jan. 3, 2024, 1:30 p.m. No.20177268   🗄️.is 🔗kun   >>7565 >>7632

https://twitter.com/joshg99/status/1737766492999995721

 

Josh Guetzkow

@joshg99

Well, there we have it in black and white folks: Pfizer never did the study they said they would do comparing process 1 and 2 in humans subjects. They decided in Sept. 2022 that it was "no longer warranted." 🤷‍♂️

@Kevin_McKernan

@P_J_Buckhaults

@ChrisEd16512812

Quote

a_concerned_amyloidosis💜🐭🇩🇪

@a_nineties

·

Dec 21, 2023

🚨🚨FINAL STUDY REPORTS FOR C4591001/BNT162-01 ARE AVALABLE🚨🚨

C4591001: https://mega.nz/folder/LZJ31KqK#m1Z6XM90LFNaoFn4KGkYgA

BNT162-01: https://mega.nz/folder/SR5nUAKC#LQ8NT55wTjKy0z_4OW4IAg

uploaded on EMA CDP december 19&20. just saw and re-upped, will be reading these files!

Show more

3:26 AM · Dec 21, 2023

Anonymous ID: ccfaf6 Jan. 3, 2024, 1:34 p.m. No.20177292   🗄️.is 🔗kun

https://twitter.com/nicksortor/status/1738381534955213054

 

Nick Sortor

@nicksortor

🚨 DECEMBER LAHAINA, MAUI UPDATE:

 

The local, state, and federal governments have done practically NOTHING for the residents of Maui in the past several months

 

⚠️ Over 800 small businesses have now closed down

 

⚠️ THOUSANDS of residents have already been forced off the island, with thousands more having to leave next month=

 

⚠️ Many who have lost their jobs have received next to NOTHING, countless more will lose unemployment benefits in January

 

⚠️ Some residents are literally being forced to LIVE ON THE BEACH

 

⚠️ The government LIED about small business bridge loans, leaving them no choice but to shut down

 

❗️🚨 PLEASE do what you can to help these folks! They're getting totally SHAFTED by the government!

Anonymous ID: ccfaf6 Jan. 3, 2024, 2:10 p.m. No.20177522   🗄️.is 🔗kun   >>7527 >>7565 >>7632

>>20177250

They should know, they made it.

 

DARPA contracted pfizer, moderna, etc years ago to craft mrna gene editing technology, to spec. They know what they made, now they just want to know how well it worked and how to tweak it.

 

+++++

 

Contracted by darpa in 2013 to make the mrna gene editing technology. in other words, the US govt and citizen tax dollars affected genocide and genetically engineered immunocompromise. According to a plan.

 

Pfizer AND moderna were contracted assets for the US MILITARY via darpa, aka the DOD and US gov't. in 2013. For mrna bio-nano technology

 

darpa Awards moderna therapeutics A Grant For Up to $25 Million to Develop Messenger RNA therapeutics™ (2013)

https://www.prnewswire.com/news-releases/darpa-awards-moderna-therapeutics-a-grant-for-up-to-25-million-to-develop-messenger-rna-therapeutics-226115821.html

 

CAMBRIDGE, Mass., Oct. 2, 2013 /PRNewswire/ - moderna Therapeutics, the company pioneering messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that the Defense Advanced Research Projects Agency (darpa) has awarded the company up to $25 million to research and develop its messenger RNA therapeutics™ platform as a rapid and reliable way to make antibody-producing drugs to protect against a wide range of known and unknown emerging infectious diseases and engineered biological threats.

 

Messenger RNA therapeutics™ can be designed to tap directly into the body's natural processes to produce antibodies without exposing people to a weakened or inactivated virus or pathogen, as is the case with the vaccine approaches currently being tested. As a result, moderna's messenger RNA therapeutics™ platform has the potential to speed the development and manufacture of treatments that can produce a safer, more reliable and more robust immune response than existing technologies.

 

"We are honored to be chosen by darpa for this important grant, which will greatly accelerate our efforts to develop antibody messenger RNA therapeutics™ to combat a wide range of infectious diseases," said Stephane Bancel, president and founding CEO of moderna. "We were awarded this major grant after an intense and rigorous scientific review, and it is a testament to our team's progress and to the profound implications of messenger RNA therapeutics™ that our work was funded. We look forward to further expanding the development of our platform into this critically important new therapeutic area."

 

This $24.6 million grant could support research for up to 5 years to advance promising antibody- producing drug candidates into preclinical testing and human clinical trials. The company also received a $0.7 million "seedling" grant from darpa in March to begin work on the project.

 

This grant is part of a darpa program called ADEPT: PROTECT (Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious). The goal is to develop platform technologies that can be deployed safely and rapidly to provide the U.S. population with near-immediate protection against emerging infectious diseases and engineered biological weapons, even in cases when the pathogen or infectious agent is unknown.

 

Pfizer Awarded darpa Biodefense Contract - DoD Daily Contracts 2013

https://news.clearancejobs.com/2013/12/04/pfizer-awarded-darpa-biodefense-contract-dod-daily-contracts/

 

Pfizer, inc., has been awarded a $7,670,632 technology investment agreement. Pfizer shall perform a research and development program designed to develop a technology platform to identify and subsequently induce the production of protective antibodies to an emerging pathogen directly in an infected or exposed individual. Work will be performed in Cambridge, Mass. The estimated completion date is Dec. 8, 2016. Fiscal 2013 research and development funds are being obligated at time of award. The contracting activity is the Defense Advanced Research Projects Agency, Arlington, Va., (HR0011-14-3-0001).

Anonymous ID: ccfaf6 Jan. 3, 2024, 2:11 p.m. No.20177527   🗄️.is 🔗kun   >>7565 >>7632

>>20177522

Moderna and Pfizer were contracted at lleast as early as 2013 to craft mrna gene-editing technology.

 

The US Military /US Govt is the culprit.

Either moderna and pfizer failed to deliver on their contractual product delivery obligations, or they built exactly to spec, on contract and on schedule.

 

Removing the Viral Threat: Two Months to Stop Pandemic X from Taking Hold (2017)

 

darpa aims to develop an integrated end-to-end platform that uses nucleic acid sequences to halt the spread of viral infections in sixty days or less

 

Over the past several years, darpa-funded researchers have pioneered RNA vaccine technology, a medical countermeasure against infectious diseases that uses coded genetic constructs to stimulate production of viral proteins in the body, which in turn can trigger a protective antibody response.As a follow-on effort, darpa funded research into genetic constructs that can directly stimulate production of antibodies in the body.1,2 darpa is now launching the Pandemic Prevention Platform (P3) program, aimed at developing that foundational work into an entire system capable of halting the spread of any viral disease outbreak before it can escalate to pandemic status. Such a capability would offer a stark contrast to the state of the art for developing and deploying traditional vaccines-a process that does not deliver treatments to patients until months, years, or even decades after a viral threat emerges.

 

"darpa's goal is to create a technology platform that can place a protective treatment into health providers' hands within 60 days of a pathogen being identified, and have that treatment induce protection in patients within three days of administration. We need to be able to move at this speed considering how quickly outbreaks can get out of control," said Matt Hepburn, the P3 Program Manager. "The technology needs to work on any viral disease, whether it's one humans have faced before or not."

 

Recent outbreaks of viral infectious diseases such as Zika, H1N1 influenza, and Ebola have cast into sharp relief the inability of the global health system to rapidly contain the spread of a disease using existing tools and procedures. State-of-the-art medical countermeasures typically take many months or even years to develop, produce, distribute, and administer. These solutions often arrive too late-if at all-and in quantities too small to respond to emerging threats. in contrast, the envisioned P3 platform would cut response time to weeks and stay within the window of relevance for containing an outbreak.

 

Key to this undertaking are nucleic-acid-based technologies-those that are centered on DNA and RNA-including some developed under darpa's Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program. Using these tools, scientists can identify protective antibodies from recovering patients and then, through a biological version of reverse engineering, manufacture genetic constructs that, when delivered, can instruct an individual's body to produce similar protective antibodies. Significant quantities of these nucleic acid "blueprints" can be rapidly manufactured compared to state-of-the-art antibody production methods.

 

https://www.darpa.mil/news-events/2017-02-06a

 

Army General to Co-Lead 'Operation Warp Speed' for COVID-19 Vaccine

 

https://www.defense.gov/News/News-Stories/Article/Article/2188680/army-general-to-co-lead-operation-warp-speed-for-covid-19-vaccine/

p1